Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMDMQW0)

Drug Name
SAR-100842 Drug Info
Synonyms LPA1/LPA3 antagonist (renal fibrosis), sanofi-aventis
Indication
Disease Entry ICD 11 Status REF
Fibrosis GA14-GC01 Phase 2 [1]
Systemic sclerosis 4A42 Phase 2 [2]
Cross-matching ID
PubChem CID
44481866
CAS Number
CAS 1195941-38-8
TTD Drug ID
DMDMQW0

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lysophosphatidate-3 receptor (LPAR3) TTE2YJR LPAR3_HUMAN Modulator [3]
Lysophosphatidic acid receptor 1 (LPAR1) TTQ6S1K LPAR1_HUMAN Modulator [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Lysophosphatidic acid receptor 1 (LPAR1) DTT LPAR1 5.998 6.919 6.589 6.975
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Fibrosis
ICD Disease Classification GA14-GC01
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Lysophosphatidic acid receptor 1 (LPAR1) DTT LPAR1 6.48E-01 -0.04 -0.24
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01651143) Proof of Biological Activity of SAR100842 in Systemic Sclerosis. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling. Biomol Ther (Seoul) 2015 January; 23(1): 1-11.